'Musculoskeletal DTx' EverX Announces Consecutive Achievements at Domestic Conferences

EverX, a digital healthcare company specializing in musculoskeletal disorders, announced on the 31st that it presented the achievements of its musculoskeletal disorder rehabilitation exercise platform 'MORA' and Korea's first digital therapeutic device (DTx) in the musculoskeletal disorder field, 'MORA-DTx,' at major domestic academic conferences including the Korean Orthopaedic Association, the Korean Society of Sports Medicine, and the Korean Academy of Rehabilitation Medicine.

At the 63rd Autumn Scientific Conference of the Korean Society of Sports Medicine held on the 14th and 15th, Yoon Chan, CEO of EverX, gave a presentation titled "Randomized Clinical Trial to Evaluate the Clinical Efficacy and Safety of a Multidisciplinary Digital Therapeutic Device in Patients with Patellofemoral Pain Syndrome." This oral presentation was selected for the Society's Outstanding Presentation Award.
[Photo by EverX]

At the ‘2023 Korean Orthopaedic Association 67th International Academic Conference’ held from the 12th to the 14th and the ‘63rd Autumn Academic Conference of the Korean Society of Sports Medicine’ held from the 14th to the 15th, EverX presented interim results of an exploratory clinical trial evaluating the safety and efficacy of DTx incorporating cognitive behavioral therapy in the rehabilitation of patients with patellofemoral pain syndrome.

In a prospective, randomized exploratory clinical trial involving 40 patients with patellofemoral pain syndrome, the presentation of results on adherence according to performance after 8 weeks of digital therapy and changes in exercise performance confirmed high treatment adherence with approximately 70% patient exercise adherence and about 80% adherence to cognitive behavioral therapy. They also added that significant pain reduction, symptom improvement, and objective muscle strength enhancement were confirmed.

Based on these achievements, EverX also received an excellent presentation award at the Korean Society of Sports Medicine for an oral presentation titled ‘Randomized Clinical Trial to Evaluate the Clinical Efficacy and Safety of a Multidisciplinary Digital Therapeutic Device in Patients with Patellofemoral Pain Syndrome.’

Patellofemoral pain syndrome is a condition for which rehabilitation and exercise therapy are primarily recommended, and cognitive behavioral therapy is also necessary due to cognitive distortions caused by chronic pain. Considering the characteristics of this disease, EverX developed the multidisciplinary DTx ‘MORA-DTx’ and is conducting exploratory clinical trials to prove its clinical utility. They plan to proceed to confirmatory clinical trials within next year.

Furthermore, on the 27th, EverX participated in the ‘2023 Korean Academy of Rehabilitation Medicine Autumn International Academic Conference’ and presented research results evaluating the accuracy and reliability of the artificial intelligence (AI)-based pose estimation model, a core technology of the MORA platform. This study was conducted as part of the process to verify accuracy and advance technology since MORA is a solution used in medical environments. As a result, compared to existing standard pose estimation devices that require multiple sensors, the MORA platform’s pose estimation AI model demonstrated the ability to estimate joints with equivalent accuracy without additional sensors, confirming its potential as a mobile joint estimation device with accuracy and reliability.

Yoon Chan, CEO of EverX, said, “Many patients have faced difficulties in receiving smooth treatment due to practical constraints in musculoskeletal disorders where rehabilitation and exercise therapy are recommended as first-line treatments.” He added, “This study is a signal confirming the potential of DTx as a new treatment option in the musculoskeletal field.” He continued, “The achievements at domestic academic conferences, including the excellent presentation award at the Korean Society of Sports Medicine, are significant in that MORA-DTx has been recognized for its research significance as a new treatment option for musculoskeletal disorders.” He concluded, “We will expand the indications to diseases that are easy to treat with DTx and gradually increase the usefulness of DTx in musculoskeletal disorders.”

This content was produced with the assistance of AI translation services.